Literature DB >> 16810502

Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma.

Koji Fukui1, Shinji Tamura, Akira Wada, Yoshihiro Kamada, Yoshiyuki Sawai, Kazuho Imanaka, Takahiko Kudara, Iichiro Shimomura, Norio Hayashi.   

Abstract

The Rho sub-family of proteins is involved in regulating the organization of the cytoskeleton and in cell motility. Our aim is to clarify the clinical significance of Rho protein in hepatocellular carcinomas (HCC) and to determine the relationship between the level of expression and patient outcome following hepatectomy. The expression of RhoA protein in HCC and corresponding non-tumor tissues of 26 patients who underwent surgical resection was analyzed by immunoblotting. The expression level of each case was calculated as tumor/non-tumor (T/N) ratios. High expression (T/N> or =1) of RhoA protein in HCC compared to the paired non-tumor tissues was recognized in 18 patients (69.2%) of 26 samples. The activity of RhoA is also increased in HCC with high expression of RhoA. The high expression of RhoA protein did not correlate with various clinical parameters. However, the disease-free survival rates of the RhoA-high expression group (T/N> or =1) were significantly lower than those of the RhoA-low expression group (T/N<1) (P<0.05). The high expression of RhoA protein in HCC plays an important role in intrahepatic recurrence of patients who underwent a hepatectomy for HCC, and RhoA is a useful marker for predicting early recurrence in an early-stage HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16810502     DOI: 10.1007/s00432-006-0107-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

Review 1.  The GTPase superfamily: a conserved switch for diverse cell functions.

Authors:  H R Bourne; D A Sanders; F McCormick
Journal:  Nature       Date:  1990-11-08       Impact factor: 49.962

2.  An essential part for Rho-associated kinase in the transcellular invasion of tumor cells.

Authors:  K Itoh; K Yoshioka; H Akedo; M Uehata; T Ishizaki; S Narumiya
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity.

Authors:  Thomas Ho-Yin Leung; Yick-Pang Ching; Judy Wai Ping Yam; Chun-Ming Wong; Tai-On Yau; Dong-Yan Jin; Irene Oi-Lin Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

4.  Tumorigenic activity of rho genes from Aplysia californica.

Authors:  R Perona; P Esteve; B Jiménez; R P Ballestero; S Ramón y Cajal; J C Lacal
Journal:  Oncogene       Date:  1993-05       Impact factor: 9.867

5.  Characterization and expression of the human rhoH12 gene product.

Authors:  H Avraham; R A Weinberg
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

6.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

7.  Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.

Authors:  Yick-Pang Ching; Chun-Ming Wong; Shing-Fai Chan; Thomas Ho-Yin Leung; David Chi-Heng Ng; Dong-Yan Jin; Irene Oi-lin Ng
Journal:  J Biol Chem       Date:  2003-01-16       Impact factor: 5.157

Review 8.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

9.  Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma.

Authors:  K Ikeda; S Saitoh; A Tsubota; Y Arase; K Chayama; H Kumada; G Watanabe; M Tsurumaru
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

10.  Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton.

Authors:  X D Ren; W B Kiosses; M A Schwartz
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

View more
  12 in total

1.  MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility.

Authors:  Felice Ho-Ching Tsang; Sandy Leung-Kuen Au; Lai Wei; Dorothy Ngo-Yin Fan; Joyce Man-Fong Lee; Carmen Chak-Lui Wong; Irene Oi-Lin Ng; Chun-Ming Wong
Journal:  Front Med       Date:  2015-08-19       Impact factor: 4.592

2.  Overexpression of engulfment and cell motility 1 promotes cell invasion and migration of hepatocellular carcinoma.

Authors:  Jiarui Jiang; Guoqing Liu; Xiongying Miao; Songwen Hua; Dewu Zhong
Journal:  Exp Ther Med       Date:  2011-03-18       Impact factor: 2.447

3.  A network-based maximum link approach towards MS identifies potentially important roles for undetected ARRB1/2 and ACTB in liver cancer progression.

Authors:  Wilson Wen Bin Goh; Yie Hou Lee; Zubaidah M Ramdzan; Maxey C M Chung; Limsoon Wong; Marek J Sergot
Journal:  Int J Bioinform Res Appl       Date:  2012

4.  Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo.

Authors:  Ines M Macias-Perez; Roy Zent; Monica Carmosino; Matthew D Breyer; Richard M Breyer; Ambra Pozzi
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

5.  DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Authors:  Wen Xue; Alexander Krasnitz; Robert Lucito; Raffaella Sordella; Linda Vanaelst; Carlos Cordon-Cardo; Stephan Singer; Florian Kuehnel; Michael Wigler; Scott Powers; Lars Zender; Scott W Lowe
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

6.  Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?

Authors:  Amanda B Cooper; Jianmin Wu; Debao Lu; Mary A Maluccio
Journal:  J Gastrointest Surg       Date:  2007-09-25       Impact factor: 3.452

7.  Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.

Authors:  Takashi Toyama; Han Chu Lee; Hironori Koga; Jack R Wands; Miran Kim
Journal:  Mol Cancer Res       Date:  2010-01-26       Impact factor: 5.852

8.  Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma.

Authors:  Annemilaï Tijeras-Raballand; Patricia Hainaud-Hakim; Jean-Olivier Contreres; Caroline Gest; Carole Le Henaff; Bernard I Levy; Marc Pocard; Claudine Soria; Evelyne Dupuy
Journal:  Gastroenterol Res Pract       Date:  2011-02-22       Impact factor: 2.260

9.  Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma.

Authors:  Jenny Chan; Frankie Chi Fat Ko; Yin-Shan Yeung; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

10.  MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA.

Authors:  Sheng-Chun Wang; Xiao-Lin Lin; Jing Li; Ting-Ting Zhang; Hui-Yan Wang; Jun-Wen Shi; Sheng Yang; Wen-Tao Zhao; Rao-Ying Xie; Fang Wei; Yu-Juan Qin; Lin Chen; Jie Yang; Kai-Tai Yao; Dong Xiao
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.